Cancer Therapy Advisor (3/1, Bennett) reports, “The number of genes tested for ovarian and breast cancer has grown in recent years, but most patients do not undergo testing. Thus, variant-of-unknown-significance (VUS) results are common, especially among minority populations, according to the results of a study published in the Journal of Clinical Oncology.” The study “results revealed that testing was done in only 34% of patients with ovarian cancer and 25% of patients with breast cancer.” What’s more, even though “the number of genes tested grew each year by 28% and the rates of detection of VUS also increased markedly, the number of patients undergoing testing rose each year by only 2%.”
